Pfizer company profile
Company profile
Pfizer has 75,000 employees and is headquartered in New York, United States.
Biopharmaceutical products form the core of the business, organized into three segments: Biopharma, PC1 and Pfizer Ignite. Internal medicine includes Eliquis for cardiovascular metabolic diseases, Nurtec ODT/Vydura and Zavzpret for migraine, the Prevnar family and Abrysvo among vaccines, and Paxlovid for COVID-19. Inflammation and immunology products include Xeljanz, Enbrel and Cibinqo, while rare disease treatments cover amyloidosis, hemophilia and endocrine diseases with the Vyndaqel family, Genotropin and BeneFIX. Oncology spans antibody-drug conjugates, small molecules and immunotherapies under brands such as Ibrance, Xtandi and Padcev, along with biosimilars such as Inflectra. Collaborations exist with Bristol-Myers Squibb, Astellas, Merck KGaA and BioNTech, and with Boltz, PBC on biomolecular AI foundation models.
In the fiscal year ended December 2025, revenue was 62.6 billion US dollars, down 1.6% from the prior year, and net income reached 7.8 billion dollars. The United States generated 59.2% of revenue, international developed markets 25.9% and international emerging markets 14.9%. The company employs 75,000 people and is headquartered in New York, where it was founded in 1849.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Headquarters
- 66 Hudson Boulevard East, 10001-2192, New York
- Employees
- 75,000
- Chief executive
- Albert Bourla
- Founded
- 1849
- Fiscal year
- January - December
- Listing
- PFE · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US7170811035
- Website
- pfizer.com
Pfizer and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| PfizerPFE | United States | $164.5B | 75,000 | 29.1% | 41.2 |
| Gilead SciencesGILD | United States | $207.86B | 17,000 | 38.2% | — |
| Bristol-Myers SquibbBMY | United States | $125.4B | 32,500 | 32.4% | 13.6 |
| AmgenAMGN | United States | $250.07B | 31,500 | 34.1% | 26.8 |
| Merck & Co.MRK | United States | $356.13B | 73,000 | 35.2% | 144.5 |
| AbbVieABBV | United States | $520.65B | 57,000 | 36.6% | 50.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
